Zusammenfassung
Die klinisch-körperliche Untersuchung, die Knochendichtemessung
und radiomorphometrische Verfahren sind die Hauptstützen der
Osteoporosediagnostik. Eine begrenzte Zahl einfacher Laborparameter reicht
meistens aus, um sekundäre Formen einer Osteoporosen und eine Osteomalazie
abzugrenzen. Knochenspezifische Umbauparameter spielen eine wachsende Rolle
beim Therapiemonitoring. Sie könnten in den kommenden Jahren auch eine
Rolle in der Therapieentscheidung spielen. Bei unklaren oder inkonsistenten
Befunden ist eine Knochenbiopsie hilfreich. Der Artikel gibt einen aktuellen
Überblick über die Möglichkeiten und Grenzen der oben genannten
diagnostischen Verfahren.
Abstract
Physical examination, bone densitometry and x-ray are the mainstay
in the evaluation of osteoporosis. A limited number of simple blood tests are
sufficient to discriminate most secondary forms of osteoporosis and to exclude
osteomalacia. Bone-specific biochemical markers play an increasing role in
monitoring osteoporosis therapy. They may also play a role in treatment
decision in the coming years. Bone biopsies are helpful if findings are unclear
or inconsistent. The present review gives a summary of the opportunities and
limitations of the above diagnostic procedures.
Schlüsselwörter
Osteoporose - Knochendichtemessung - Osteosonometrie - Knochenbiopsie - Biochemische
Marker - Genetische Marker
Key words
Osteoporosis - Bone
Densitometry - Osteosonometry - Bone
Biopsy - Biochemical Markers - Genetic Markers
Literatur
- 1
Baran D T, Kelly A M, Karellas A. et al .
Ultrasound of the os calcis in women with osteoporosis and
hip fractures.
Calcif Tissue
Int.
1988;
43
138-142
- 2
Kann P, Schulz U, Klaus D, Piepkorn B, Beyer J.
In-vivo investigation of material quality of bone tissue by
measuring apparent phalangeal ultrasound transmission velocity.
Clin
Rheumatol.
1995;
14
26-34
- 3 Kann P. Basics of ultrasound methods for bone
analysis. Schönau E Pediatric Osteology - New
Developments in Diagnostics and
Therapy Amsterdam; Elsevier 1996a: 161-167
- 4
Kann P, Scholz-Ahrens K, Schrezenmeir J, Beyer J.
Investigation of bone hardness using a modified Vickers
diamond method.
Exp Clin
Endocrinol.
1996b;
104
57
(Suppl
1)
- 5
Pfeilschifter J.
Jahresbericht der Sektion Calcium-Regulierende Hormone und
Knochenstoffwechsel (CRHUKS).
Endokrinologie
Informationen.
2000;
24
70-73
- 6
Melton I II
LJ, Chrischilles E A, Cooper C, Lane A W, Riggs B L.
How many women have osteoporosis?.
J Bone Miner
Res.
1992;
7
1005-1010
- 7
Cummings S R, Black D M, Nevitt M C. et al .
Bone density at various sites for predicting of hip
fractures.
Lancet.
1993;
341
72-75
- 8
Hans D, Dargent-Molina P, Schott A M. et al .
Ultrasonographic heel measurements to predict hip fracture in
elderly women: the EPIDOS prospective
study.
Lancet.
1996;
348
511-514
- 9
Ettinger B, Block J E, Smith R. et al .
An examination of the association between vertebral
deformities, physical disabilities and psychosocial
problems.
Maturitas.
1988;
10
238-296
- 10
Melton I I
LJ, Kann S H, Frye M A, Wahner H W, O’Fallon W M, Riggs B L.
Epidemiology of vertebral fractures in women.
Amer
J
Epidem.
1989;
129
1000-1011
- 11 Hansen M A, Overgaard K, Gotfredsen C. Does the prevalence of vertebral fractures
increase?. Christiansen C, Overgaard K Osteoporosis 1990,
Vol.
1 Kopenhagen; 1990: 95-97
- 12
Riis S BJ, Hansen A M, Jensen K, Overgaard K, Christiansen C.
Low bone mass and fast rate of bone loss at menopause-equal
risk factors for future fracture. A 15 year follow-up
study.
Bone.
1996;
19
9-12
- 13
Sambrook P N, Jones G.
Corticosteroid Osteoporosis.
Br J
Rheumatol.
1995;
34
8-12
- 14
Storm T, Thamsborg G, Steiniche T, Genant H K, Sorensen O H.
Effect of intermittent cyclical etidronate therapy on bone
mass and fracture rate in women with postmenopausal osteoporosis.
New
Engl J
Med.
1990;
322
1265-1271
- 15
Liberman U A, Weiss S R, Bröll J. et al .
Effect of oral alendronate on bone mineral density and the
incidence of fracture in postmenopausal osteoporosis.
New Engl J
Med.
1995;
333
1437-1443
- 16
Black D M, Cummings S R, Karpf D B. et al .
Randomisedtrail of effect of a alendronate on risk of
fracture in women with existing vertebral
fractures.
Lancet.
1996;
348
1535-1541
- 17
Ettinger B, Black D M, Mitlak B H. et al .
Reduction of vertebral fracture risk in postmenopausal women
with osteoporosis treated with
raloxifene.
JAMA.
1999;
282
637-645
- 18
Harris S T, Watts N B, Genant H K. et al .
Ultrasaound velocity through bone predicts incident vertebral
deformity.
J Bone Miner
Res.
1995;
3
341-345
- 19
Reginster J -Y, Minne H W, Sorensen O H. et al .
Randomized trial of the effects of risedronate on vertebral
fractures in women with established postmenopausal
osteoporosis.
Osteoporosis
Int.
2000;
11
83-91
- 20
Riggs B L, Hodgson S F, O’Fallon W M, Chao E Y, Wahner H W, Muhs J M.
Effect of fluoride treatment on the fracture rate in
postmenopausal women with osteoporosis.
New Engl J
Med.
1990;
322
802-809
- 21
Kleerekoper M, Mendlovic D B.
Sodium fluoride therapy of postmenopausal
osteoporosis.
Endocr
Rev.
1993;
14
312-323
- 22
Porter R W, Miller C G, Grainger D, Palmer S B.
Prediction of hip fracture in elderly women: a prospective
study.
Br Med
J.
1990;
301
638-641
- 23
Waud C E, Low R, Baran D T.
The relationship between ultrasound and densitometric
measurements of bone mass at the calcaneus in women.
Calcif Tissue
Int.
1992;
51
415-418
- 24
Schott A M, Weill-Engerer S, Hans D, Duboeuf F, Delmas P D, Meunier P J.
Ultrasound discriminates patients with hip fractures equaly
well as dual energy x-ray absorptiometry and independently of bone mineral
density.
L Bone Miner
Res.
1995;
2
243-249
- 25
Wüster C, Albanese C, de
Aloysio D. et al .
Phalangeal osteosonogrammetry study: age-related changes,
diagnostic sensitivity, and discrimination power.
J Bone Miner
Res.
2000;
15
1603-1614
- 26
Eisman J A.
Genetics of osteoporosis.
Endocrine
Rev.
1999;
20
788-804
- 27
Kann P, Fang Y, Bergink A P. et al .
The Collagen I ( 1 Sp1 Polymorphism is associated with
differences in ultrasound transmission velocity in the calcaneus in
postmenopausal women.
Calcif Tissue Int.
in
press
- 28
Riancho J A.
Number of patients to be treated and number of prevented
fractures: clinical efficiency of osteoporosis treatment with diphophonate
alendronate.
Rev Clin
Esp.
1999;
199
349-355
- 29
Thorsen K, Kristofferson A, Lorenzton R.
The effects of brisk walking on markers of bone and calcium
metabolism in postmenopausal women.
Calcif Tissue
Int.
1996;
58
221-225
- 30
Ingle B M, Hay S M, Bottjer H M, Eastell R.
Changes in bone mass and bone turnover following distal
forearm fracture.
Osteoporosis
Int.
1999;
10
399-407
- 31
Zerwekh J E, Ruml L A, Gottschalk F, Pak C Y.
The effects of twelve weeks of bed rest on bone histology,
biochemical markers of bone turnover, and calcium homeostasis in eleven normal
subjects.
J Bone Miner
Res.
1998;
13
1594-1601
- 32
Garnero P, Sornay-Rendu E, Chapuy M C, Delmas P D.
Increased bone turnover in late postmenopausal women is a
major determinant of osteoporosis.
J Bone Mineral
Res.
1996;
11
337-349
- 33
Garnero P, Hausherr E, Chapuy M C.
et al. Markers of bone resorption predict hip fracture in
elderly women: The Epidos prospective study.
J Bone Miner
Res.
1996;
11
1531-1538
- 34
Ross P D, Kress B C, Parson R E, Wasnich R D, Armour K A, Mizrahi I A.
Serum bone alkaline phosphatase and calcaneus bone density
predict fractures: A prospective study.
Osteoporos
Int.
2000;
11
76-82
- 35
Calvo M S, Eyre D R, Gundberg C M.
Molecular basis and clinical application of biological
markers of bone turnover.
Endocrine
Rev.
1996;
17
333-368
- 36
van
Daele P LA, Seibel M J, Burger H. et al .
Case-control analysis of bone resorption markers, disability,
and hip fracture risk: The Rotterdam study.
Brit Med
J.
1996;
312
482-483
- 37
Szulc P, Chapuy M C, Meunier P J, Delmas P D.
Serum undercarboxylated osteocalcin is a marker of the risk
of hip fracture in elderly women.
J Clin
Invest.
1993;
91
1769-1774
- 38
Szulc P, Chapuy M C, Meunier P J, Delmas P D.
Serum undercarboxylated osteoclacin is a marker of the riks
of hip fracture: a three year follow-up
study.
Bone.
1996;
5
487-488
- 39
Vergnaud P, Garnero P, Meunier P J, Breart G, Kamihagi K, Delmas P D.
Undercarboxylated osteoclacin measured with a specific
immunoassay predicts hip fracture in elderly women: the EPIDOS
study.
J Clin Endocrinol
Metab.
1997;
82
719-724
- 40
Keen R W, Nguyen T, Sobnack R, Perry L A, Thompson P W, Spector T D.
Can biochemical markers predict bone loss at the hip and
spine? a 4-year prospective study of 141 early postmenopausal
women.
Osteoporosis
Int.
1996;
6
399-406
- 41
Chestnut C H, Bell N H, Clark G S. et al .
Hormone replacement therapy in postmenopausal women: urinary
N-teopeptide of type I collagen monitors therapeutic effect and predicts
response of bone mineral density.
Am J
Med.
1997;
102
29-37
- 42
Ravn P, Clemmesen B, Christiansen C.
Biochemical markers can predict the responses in bone mass
during alendronate treatment in early postmenopausal
women.
Bone.
1999;
24
237-244
- 43
Yoshimura N, Hashimoto T, Sakata K, Morioka S, Kasamatsu T, Cooper C.
Biochemical markers of bone turnover and bone loss at the
lumbar spine and femoral neck: the Taiji Study.
Calcif Tissue
Int.
1999;
65
198-202
- 44
Chaki O, Yoshikata I, Kikuchi R. et al .
The predictive value of biochemical markers of bone turnover
for bone mineral density in postmenopausal Japanese women.
J Bone
Miner
Res.
2000;
15
1537-1544
- 45
Melton L J
3rd, Atkinson E J, O’Connor M K, O’Fallon W M, Riggs B L.
Determinants of bone loss from the femoral neck in women of
different ages.
J Bone Mineral
Res.
2000;
15
24-31
- 46
Marcus R, Holloway L, Wells B. et al .
The relationship of biochemical markers of bone turnover to
bone density changes in postmenopausal women: results from the postmenopausal
estrogen/progestin interventions (PEPI) trial.
J Bone Miner
Res.
1999;
14
1583-1595
- 47
Scheidt-Nave C, Bismar H, Leidig-Bruckner G. et al .
Serum interleukin 6 is a major predictor of bone loss in
women specific to the first decade past menopause.
J Clin Endocrinol
Metab.
2001;
86
2032-2042
- 48
Slemenda C, Longcope C, Peacock M, Hui S, Johnston C C.
Sex steroids, bone mass, and bone loss. A prospective study
of pre-, peri-, and postmenopausal women.
J Clin
Invest.
1996;
97
14-21
- 49
Bauer D C, Sklarin P M, Stone K L. et al .
Biochemical markers of bone turnover and prediction of hip
bone loss in older women: the study of osteoporotic fractures.
J Bone
Mineral
Res.
1999;
14
1404-1410
- 50
Dennison E, Eastel R, Fall C HD. et al .
Determinants of bone loss in elderly men and women: A
prospective population-based study.
Osteoporos
Int.
1999;
10
384-391
- 51
Eastell R, Delmas P D, Hodgson S F. et al .
Bone formation rate in older normal women: concurrent
assessment with bone histomorphometry, calcium kinetics, and biochemical
markers.
J Clin Endocrinol
Metab.
1988;
67
741-748
- 52
Garnero P, Sornay-Rendu E, Duboeuf F, Delmas P D.
Markers of bone turnover predict postmenopausal forearm bone
loss over 4 years: the OFELY study.
J Bone Mineral
Res.
1999;
14
1614-1621
- 53
Johansen J S, Riis B J, Delmas P D, Christiansen C.
Plasma BGP: an indicator of spontaneous bone loss and of the
effect of oestrogen treatment in postmenopausal women.
Eur J Clin
Invest.
1988;
18
191-195
- 54
Cooper C, Stakkesdad J A, Radowicki S. et al .
Matrix delivery transdermal 17 B estradiol for the prevention
of bone loss in postmenopausal women.
Osteoporosis
Int.
1999;
9
358-366
- 55
Garnero P, Shih W J, Gineyts E, Karpf D, Delmas P D.
Comparison of new biochemical markers of bone turnover in
late postmenopausal women in response to alendronate treatment.
J
Clin Endocrinol
Metab.
1994;
79
1693-1700
- 56
Greenspan S L, Rosen H N, Parker R A.
Early changes in serum N-telopeptide and C-telopeptide
cross-linked collagen type 1 predict long-term response to alendronate therapy
in elderly women.
J Clin Endocrinol
Metab.
2000;
85
3537-3540
- 57
Delmas P D, Bjarnasson N H, Mitlak B H. et al .
Effects of raloxifene on bone mineral density, serum
cholesterol concentrations, and uterine endometrium in postmenopausal
women.
New Eng J
Med.
1997;
337
1641-1647
- 58
Heikkinen A -M, Parviainen M, Niskanen L. et al .
Biochemical bone markers and bone mineral density during
postmenopausal hormone replacement therapy with and without vitamin D3: a
prospective, controlled, randomized study.
J Clin Endocrinol
Metab.
1997;
82
2476-2482
- 59
Rosen C J, Chesnut I II
CH, Mallinak N JS.
The predictive value of biochemical markers of bone turnover
for bone mineral density in early postmenopausal women treated with hormone
replacement or calcium supplementation.
J Clin Endocrinol
Metab.
1997;
82
1904-1910
- 60
Ravn P, Christensen J O, Baumann M, Clemmesen B.
Changes in biochemical markers and bone mass after withdrawal
of ibandronate treatment: prediction of bone mass changes during
treatment.
Bone.
1998;
22
559-564
- 61
Ravn P, Hosking D, Thompson G C. et al .
Monitoring of alendronate treatment and prediction of effect
on bone mass by biochemical markers in early postmenopausal intervention cohort
of study.
J Clin Endocrinol
Metab.
1999;
84
2363-2368
- 62
Garnero P, Darte C, Delmas P D.
A model to monitor the efficacy of alendronate treatment in
women with osteoporosis using a biochemical markers of bone
turnover.
Bone.
1999;
24
603-609
- 63
Bjarnason N H, Christiansen C, Sarkar S. et al .
6 months changes in biochemical markers predict 3-year
response in vertebral fracture rate in postmenopausal, osteoporotic women:
results from the MORE study.
J Bone Miner
Res.
1999;
14
S157
(S1)
- 64
Seck T, Scheidt-Nave C, Leidig-Bruckner G, Ziegler R, Pfeilschifter J.
Low serum concentrations of insulin-like growth factor I are
associated with femoral bone loss in a population-based sample of
postmenopausal women.
Clin
Endocrinol.
2001;
55
101-106
- 65
Garnero P, Sornay-Rendu E, Delmas P D.
Low serum IGF-1 and occurence of osteoporotic fractures in
postmenopausal
women.
Lancet.
2000;
355
898-899
- 66
Stone K, Bauer D C, Black D M, Sklarin P, Ensrud K E, Cummings S R.
Hormonal predictors of bone loss in elderly owmen: a
prospective study.
J Bone Miner
Res.
1998;
13
1167-1174
- 67
Garnero P, Sornay-Rendu E, Claustrat B, Delmas P D.
Biochemical markers of bone turnover, endogenous hormones and
the risk of fractures in postmenopausal women: the OFELY Study.
J
Bone Miner
Res.
2000;
15
1526-1536
- 68
Hobson E E, Ralston S H.
Role of genetic factors in the pathophysiology and management
of osteoporosis.
Clin
Endocrinol.
2001;
54
1-9
- 69
Hinke V, Seck T, Clanget C, Scheidt-Nave C, Ziegler R, Pfeilschifter J.
Association of transforming growth factor-ß1
(TGF-ß1) T29(C gene polymorphism with bone mineral density (BMD), changes
in BMD, and serum concentrations of TGF-ß1 in a population-based sample
of postmenopausal German women.
Calcif Tissue Int.
in
Druck
Prof. Dr. J. Pfeilschifter
Berufsgenossenschaftliche Kliniken Bergmannsheil, Medizinische
Klinik - Uniklinik Bochum
Bürkle-de-la-Camp-Platz 1
44789 Bochum
Fax: 02 34-3 02 64 03
Email: Johannes.Pfeilschifter@ruhr-uni-bochum.de
